The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives

Autoimmunity Reviews

Volumn 16, Issue 12, 2017, Pages 1185-1195

  Favalli, Ennio Giulio ^a   Raimondo, Maria Gabriella ^b   Becciolini, Andrea ^a   Crotti, Chiara ^b   Biggioggero, Martina ^b   Caporali, Roberto ^c  

^a ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Biologic drugs; Failures; Rheumatoid arthritis; TNF inhibitors; Treatment strategy

Indexed keywords

JANUS KINASE INHIBITOR; ANTIRHEUMATIC AGENT;

BIOLOGICAL THERAPY; CLINICAL PRACTICE; DRUG TREATMENT FAILURE; HUMAN; MONOTHERAPY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; PROCEDURES; TREATMENT FAILURE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; HUMANS; TREATMENT FAILURE;

EID: 85031754826     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.10.002     Document Type: Review

References (132)

1. Mcinnes, I.B., Schett, G., The pathogenesis of rheumatoid arthritis. N Engl J Med 365 (2011), 2205–2219.
2. Smolen, J.S., Aletaha, D., Mcinnes, I.B., Rheumatoid arthritis. Lancet 388 (2016), 2023–2038.
3. Firestein, G.S., The disease formerly known as rheumatoid arthritis. Arthritis Res Ther, 16, 2014, 114.
4. Schipper, L.G., Vermeer, M., Kuper, H.H., Hoekstra, M.O., Haagsma, C.J., den AA, Broeder, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch rheumatoid arthritis monitoring registry. Ann Rheum Dis 71 (2012), 845–850.
5. Vermeer, M., Kuper, H.H., Bernelot Moens, H.J., Hoekstra, M., Posthumus, M.D., van Riel, P.L.C.M., et al. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Res Ther, 14, 2012, R254.
6. Smolen, J.S., Breedveld, F.C., Burmester, G.R., Bykerk, V., Dougados, M., Emery, P., et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75 (2016), 3–15.
7. Singh, J.A., Saag, K.G., Bridges, S.L., Akl, E.A., Bannuru, R.R., Sullivan, M.C., et al. American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68 (2015), 1–26 2016.
8. Smolen, J.S., Landewé, R., Bijlsma, J., Burmester, G.R., Chatzidionysiou, K., Dougados, M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis, 2017 (annrheumdis–2016–210715).
9. Atzeni, F., Benucci, M., Sallì, S., Bongiovanni, S., Boccassini, L., Sarzi-Puttini, P., Different effects of biological drugs in rheumatoid arthritis. Autoimmun Rev 12 (2013), 575–579.
10. Lipsky, P.E., van der Heijde, D.M., Clair, E.W.S., Furst, D.E., Breedveld, F.C., Kalden, J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343 (2000), 1594–1602.
11. Klareskog, L., van der Heijde, D.M., de Jager, J.P., Gough, A., Kalden, J.R., Malaise, M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004), 675–681.
12. Keystone, E.C., Kavanaugh, A., Sharp, J.T., Tannenbaum, H., Hua, Y., Teoh, L.S., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 (2004), 1400–1411.
13. Smolen, J.S., Landewé, R., Mease, P.J., Brzezicki, J., Mason, D., Luijtens, K., et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 68 (2009), 797–804.
14. Keystone, E.C., Genovese, M.C., Klareskog, L., Hsia, E.C., Hall, S.T., Miranda, P.C., et al. Golimumab, a human antibody to tumour necrosis factor given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis 68 (2009), 789–796.
15. Atzeni, F., Sarzi-Puttini, P., Botsios, C., Carletto, A., Cipriani, P., Favalli, E.G., et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. 12, 2012, 225–229.
16. Favalli, E.G., Pregnolato, F., Biggioggero, M., Becciolini, A., Penatti, A.E., Marchesoni, A., et al. Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry. Arthritis Care Res 68 (2016), 432–439.
17. Marchesoni, A., Zaccara, E., Gorla, R., Bazzani, C., Sarzi-Puttini, P., Atzeni, F., et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 1173 (2009), 837–846.
18. Hetland, M.L., Christensen, I.J., Tarp, U., Dreyer, L., Hansen, A., Hansen, I.T.N., et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62 (2010), 22–32.
19. Nam, J.L., Winthrop, K.L., van Vollenhoven, R.F., Pavelka, K., Valesini, G., Hensor, E.M.A., et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69 (2010), 976–986.
20. Atzeni, F., Sarzi-Puttini, P., Gorla, R., Marchesoni, A., Caporali, R., Switching rheumatoid arthritis treatments: an update. Autoimmun Rev 10 (2011), 397–403.
21. Giacomelli, R., Afeltra, A., Alunno, A., Baldini, C., Bartoloni-Bocci, E., Berardicurti, O., et al. International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: the unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev 16:9 (2017), 911–924.
22. Dennis, G., Holweg, C.T.J., Kummerfeld, S.K., Choy, D.F., Setiadi, A.F., Hackney, J.A., et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther, 16, 2014, R90.
23. Vincent, F.B., Morand, E.F., Murphy, K., Mackay, F., Mariette, X., Marcelli, C., Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 72 (2013), 165–178.
24. Schaeverbeke, T., Truchetet, M.-E., Kostine, M., Barnetche, T., Bannwarth, B., Richez, C., Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology (Oxford) 55 (2016), 210–220.
25. Favalli, E.G., Pontikaki, I., Becciolini, A., Biggioggero, M., Ughi, N., Romano, M., et al. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. Clin Rheumatol 31 (2017), 390–399.
26. Polido-Pereira, J., Vieira-Sousa, E., Fonseca, J.E., Rheumatoid arthritis: what is refractory disease and how to manage it?. Autoimmun Rev 10 (2011), 707–713.
27. Kremer, J.M., Genant, H.K., Moreland, L.W., Russell, A.S., Emery, P., Abud-Mendoza, C., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144 (2006), 865–876.
28. Smolen, J.S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371 (2008), 987–997.
29. Emery, P., Breedveld, F.C., Hall, S., Durez, P., Chang, D.J., Robertson, D., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372 (2008), 375–382.
30. St Clair, E.W., van der Heijde, D.M., Smolen, J.S., Maini, R.N., Bathon, J.M., Emery, P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50 (2004), 3432–3443.
31. Breedveld, F.C., Weisman, M.H., Kavanaugh, A., Cohen, S.B., Pavelka, K., van Vollenhoven, R.F., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2005), 26–37.
32. Emery, P., Bingham, C.O., Burmester, G.R., Bykerk, V.P., Furst, D.E., Mariette, X., et al. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis 76 (2017), 96–104.
33. Emery, P., Fleischmann, R.M., Moreland, L.W., Hsia, E.C., Strusberg, I., Durez, P., et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60 (2009), 2272–2283.
34. Westhovens, R., Robles, M., Ximenes, A.C., Nayiager, S., Wollenhaupt, J., Durez, P., et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68 (2009), 1870–1877.
35. Burmester, G.R., Rigby, W.F., van Vollenhoven, R.F., Kay, J., Rubbert-Roth, A., Kelman, A., et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis 75 (2016), 1081–1091.
36. Soliman, M.M., Ashcroft, D.M., Watson, K.D., Lunt, M., Symmons, D.P.M., Hyrich, K.L., et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology biologics register. Ann Rheum Dis 70 (2011), 583–589.
37. Kievit, W., Fransen, J., Adang, E.M.M., den AA, Broeder, Bernelot Moens, H.J., Visser, H., et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch rheumatoid arthritis monitoring register. Rheumatology (Oxford) 50 (2011), 196–203.
38. Neovius, M., Arkema, E.V., Olsson, H., Eriksson, J.K., Kristensen, L.E., Simard, J.F., et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 74 (2015), 354–360.
39. Iannone, F., Gremese, E., Atzeni, F., Biasi, D., Botsios, C., Cipriani, P., et al. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 39 (2012), 1179–1184.
40. Pan, Du S.M., Dehler, S., Ciurea, A., Ziswiler, H.-R., Gabay, C., Finckh, A., et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 61 (2009), 560–568.
41. Forsblad-d'Elia, H., Bengtsson, K., Kristensen, L.E., Jacobsson, L.T.H., Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register. Rheumatology (Oxford) 54 (2015), 1186–1193.
42. Gabay, C., Riek, M., Hetland, M.L., Hauge, E.-M., Pavelka, K., Tomsic, M., et al. Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. Ann Rheum Dis 75 (2016), 1336–1342.
43. Nüßlein, H.G., Alten, R., Galeazzi, M., Lorenz, H.-M., Nurmohamed, M.T., Bensen, W.G., et al. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. Clin Exp Rheumatol 34 (2016), 489–499.
44. Kiely, P.D.W., Biologic efficacy optimization-a step towards personalized medicine. Rheumatology (Oxford) 55 (2015), 780–788.
45. Smolen, J.S., Weinblatt, M.E., When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?. Ann Rheum Dis 67 (2008), 1497–1498.
46. St Clair, E.W., Wagner, C.L., Fasanmade, A.A., Wang, B., Schaible, T., Kavanaugh, A., et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002), 1451–1459.
47. Rahman, M.U., Strusberg, I., Geusens, P., Berman, A., Yocum, D., Baker, D., et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 66 (2007), 1233–1238.
48. Weinblatt, M.E., Schiff, M.H., Ruderman, E.M., Bingham, C.O., Li, J., Louie, J., et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug–controlled study. Arthritis Rheum 58 (2008), 1921–1930.
49. Curtis, J.R., Chen, L., Luijtens, K., Navarro-Millan, I., Goel, N., Gervitz, L., et al. Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. Arthritis Rheum 63 (2011), 2203–2208.
50. Finckh, A., Simard, J.F., Gabay, C., Guerne, P.-A., SCQM physicians, Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 65 (2006), 746–752.
51. Ollendorf, D.A., Klingman, D., Hazard, E., Ray, S., Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther 31 (2009), 825–835.
52. Favalli, E.G., Biggioggero, M., Meroni, P.L., Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an “anchor” drug?. Autoimmun Rev 13 (2014), 1102–1108.
53. Becciolini, A., Biggioggero, M., Favalli, E.G., The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: retrospective analysis of a local registry. J Int Med Res 44 (2016), 113–118.
54. Gabay, C., Riek, M., Scherer, A., Finckh, A., SCQM collaborating physicians. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. Rheumatology (Oxford) 54 (2015), 1664–1672.
55. Cohen, S.B., Emery, P., Greenwald, M.W., Dougados, M., Furie, R.A., Genovese, M.C., et al. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54 (2006), 2793–2806.
56. Truchetet, M.-E., Poursac, N., Barnetche, T., Shipley, E., Gottenberg, J.-E., Bannwarth, B., et al. Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry. Arthritis Res Ther, 18, 2016, 72.
57. Dougados, M., Kissel, K., Conaghan, P.G., Mola, E.M., Schett, G., Gerli, R., et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 73 (2014), 803–809.
58. Huizinga, T.W.J., Conaghan, P.G., Martin-Mola, E., Schett, G., Amital, H., Xavier, R.M., et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis 74 (2015), 35–43.
59. Haraoui, B., Casado, G., Czirják, L., Taylor, A., Bernasconi, C., Reiss, W., et al. Patterns of tocilizumab use, effectiveness and safety in patients with rheumatoid arthritis: core data results from a set of multinational observational studies. Clin Exp Rheumatol, 2017.
60. Cohen, J.-D., Zaltni, S., Kaiser, M.J., Bozonnat, M.C., Jorgensen, C., Daurès, J.P., et al. Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis. Ann Rheum Dis 63 (2004), 209–210.
61. Nikiphorou, E., Negoescu, A., Fitzpatrick, J.D., Goudie, C.T., Badcock, A., Östör, A.J.K., et al. Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort. Clin Rheumatol 33 (2014), 609–614.
62. Kivity, S., Zafrir, Y., Loebstein, R., Pauzner, R., Mouallem, M., Mayan, H., Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients. Autoimmun Rev 13 (2014), 1109–1113.
63. Manara, M., Bianchi, G., Bruschi, E., Azzolini, V., Belai Beyene, N., Corbanese, S., et al. Adherence to current recommendations on the use of methotrexate in rheumatoid arthritis in Italy: results from the MARI study. Clin Exp Rheumatol 34 (2016), 473–479.
64. Burmester, G.R., Kivitz, A.J., Kupper, H., Arulmani, U., Florentinus, S., Goss, S.L., et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 74 (2015), 1037–1044.
65. Nakashima, Y., Miyahara, H., Kondo, M., Fukuda, T., Harada, H., Haraguchi, A., et al. Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: results from registered data analyses. Mod Rheumatol 27 (2017), 15–21.
66. Gallo, G., Brock, F., Kerkmann, U., Kola, B., Huizinga, T.W.J., Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage. RMD Open, 2, 2016, e000186.
67. Manders, S.H.M., Kievit, W., Adang, E., Jansen, T.J., Stolk, J.N., Visser, H., et al. Effectiveness of TNF inhibitor treatment with various methotrexate doses in patients with rheumatoid arthritis: results from clinical practice. Ann Rheum Dis 74 (2015), e24–4.
68. Romão, V.C., Lima, A., Bernardes, M., Canhão, H., Fonseca, J.E., Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?. Immunol Res 60 (2014), 289–310.
69. Bianchi, G., Caporali, R., Todoerti, M., Mattana, P., Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration. Adv Ther 33 (2016), 369–378.
70. Hamilton, R.A., Kremer, J.M., Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 36 (1997), 86–90.
71. Schiff, M.H., Jaffe, J.S., Freundlich, B., Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥ 15 mg may be overcome with subcutaneous administration. Ann Rheum Dis 73 (2014), 1549–1551.
72. Braun, J., Kästner, P., Flaxenberg, P., Währisch, J., Hanke, P., Demary, W., et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 58 (2008), 73–81.
73. Hazlewood, G.S., Thorne, J.C., Pope, J.E., Lin, D., Tin, D., Boire, G., et al. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis 75 (2016), 1003–1008.
74. Branco, J.C., Barcelos, A., de Araújo, F.P., Sequeira, G., Cunha, I., Patto, J.V., et al. Utilization of subcutaneous methotrexate in rheumatoid arthritis patients after failure or intolerance to oral methotrexate: a multicenter cohort study. Adv Ther 33 (2016), 46–57.
75. Monti, S., Klersy, C., Gorla, R., Sarzi-Puttini, P., Atzeni, F., Pellerito, R., et al. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN registry. Clin Rheumatol, 2017, 1–9.
76. Strangfeld, A., Hierse, F., Kekow, J., Hinueber, von U., Tony, H.P., Dockhorn, R., et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 68 (2009), 1856–1862.
77. De Stefano, R., Frati, E., Nargi, F., Baldi, C., Menza, L., Hammoud, M., et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol 29 (2010), 517–524.
78. Buch, M.H., Rubbert-Roth, A., Ferraccioli, G., To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50. 11, 2012, 558–562.
79. Haraoui, B., Is there a rationale for switching from one anti-tumor necrosis factor agent to another?. J Rheumatol 31 (2004), 1021–1022.
80. Furst, D.E., Gaylis, N., Bray, V., Olech, E., Yocum, D., Ritter, J., et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 66 (2007), 893–899.
81. Smolen, J.S., Kay, J., Doyle, M.K., Landewé, R., Matteson, E.L., Wollenhaupt, J., et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374 (2009), 210–221.
82. Smolen, J.S., Kay, J., Doyle, M., Landewé, R., Matteson, E.L., Gaylis, N., et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Arthritis Res Ther, 17, 2015, 14.
83. Smolen, J.S., Burmester, G.R., Combe, B., Curtis, J.R., Hall, S., Haraoui, B., et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet 388 (2016), 2763–2774.
84. Weinblatt, M.E., Fleischmann, R.M., Huizinga, T.W.J., Emery, P., Pope, J., Massarotti, E.M., et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology (Oxford) 51 (2012), 2204–2214.
85. Lloyd, S., Bujkiewicz, S., Wailoo, A.J., Sutton, A.J., Scott, D., The effectiveness of anti-TNF- therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology (Oxford) 49 (2010), 2313–2321.
86. Caporali, R., Sarzi-Puttini, P., Atzeni, F., Gorla, R., Filippini, M., Marchesoni, A., et al. Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. 9, 2010, 465–469.
87. Codullo, V., Iannone, F., Sinigaglia, L., Favalli, E.G., Sarzi-Puttini, P., Atzeni, F., et al. Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. Clin Exp Rheumatol 35 (2017), 660–665.
88. Greenberg, J.D., Reed, G., Decktor, D., Harrold, L., Furst, D.E., Gibofsky, A., et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 71 (2012), 1134–1142.
89. Manara, M., Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. Clin Exp Rheumatol, 2017, 1–6.
90. Iannone, F., Santo, L., Anelli, M.G., Bucci, R., Semeraro, A., Quarta, L., et al. Golimumab in real-life settings: 2 years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum, 2017 [epub ahead of print].
91. Hyrich, K.L., Lunt, M., Watson, K.D., Symmons, D.P.M., Silman, A.J., British Society for Rheumatology Biologics Register, Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56 (2007), 13–20.
92. Virkki, L.M., Valleala, H., Takakubo, Y., Vuotila, J., Relas, H., Komulainen, R., et al. Outcomes of switching anti-TNF drugs in rheumatoid arthritis–a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol 30 (2011), 1447–1454.
93. Chatzidionysiou, K., Askling, J., Eriksson, J., Kristensen, L.E., van Vollenhoven, R.F., ARTIS group. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis 74 (2015), 890–896.
94. Blom, M., Kievit, W., Fransen, J., Kuper, I.H., den AA, Broeder, CMA, De Gendt, et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol 36 (2009), 2171–2177.
95. Lichtenstein, G.R., Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therap Adv Gastroenterol 6 (2013), 269–293.
96. Braun, J., Baraliakos, X., Listing, J., Davis, J.C., van der Heijde, D.M., Haibel, H., et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 57 (2007), 639–647.
97. Sánchez-Cano, D., Callejas-Rubio, J.L., Ruiz-Villaverde, R., Ríos-Fernández, R., Ortego-Centeno, N., Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis. Mediators Inflamm, 2013, 2013, 286857.
98. Smolen, J.S., Kay, J., Matteson, E.L., Landewé, R., Hsia, E.C., Xu, S., et al. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Ann Rheum Dis 73 (2014), 1811–1818.
99. Bombardieri, S., Ruiz, A.A., Fardellone, P., Geusens, P., McKenna, F., Unnebrink, K., et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 46 (2007), 1191–1199.
100. Lequerré, T., Farran, É., Menard, J.-F., Kozyreff-Meurice, M., Vandhuick, T., Tharasse, C., et al. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: an observational retrospective study of 72 rheumatoid arthritis switchers. Joint Bone Spine 82 (2015), 330–337.
101. Genovese, M.C., Becker, J.-C., Schiff, M.H., Luggen, M., Sherrer, Y., Kremer, J., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353 (2005), 1114–1123.
102. Genovese, M.C., Schiff, M.H., Luggen, M., Becker, J.-C., Aranda, R., Teng, J., et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67 (2008), 547–554.
103. Keystone, E.C., Emery, P., Peterfy, C.G., Tak, P.P., Cohen, S., Genovese, M.C., et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 68 (2009), 216–221.
104. Emery, P., Keystone, E.C., Tony, H.P., Cantagrel, A., van Vollenhoven, R.F., Sanchez, A., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67 (2007), 1516–1523.
105. Fleischmann, R.M., van Adelsberg, J., Lin, Y., Castelar-Pinheiro, G.D.R., Brzezicki, J., Hrycaj, P., et al. Sarilumab and nonbiologic disease-modifying Antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol 69 (2017), 277–290.
106. Harrold, L.R., Reed, G.W., Shewade, A., Magner, R., Saunders, K.C., John, A., et al. Effectiveness of rituximab for the treatment of rheumatoid arthritis in patients with prior exposure to anti-TNF: results from the CORRONA registry. J Rheumatol 42 (2015), 1090–1098.
107. Favalli, E.G., Biggioggero, M., Marchesoni, A., Meroni, P.L., Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford) 53 (2014), 1664–1668.
108. Harrold, L.R., Reed, G.W., Solomon, D.H., Curtis, J.R., Liu, M., Greenberg, J.D., et al. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. Arthritis Res Ther, 18, 2016, 280.
109. Gottenberg, J.-E., Brocq, O., Perdriger, A., Lassoued, S., Berthelot, J.-M., Wendling, D., et al. Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA 316 (2016), 1172–1180.
110. Das, S., Vital, E.M., Horton, S., Bryer, D., El-Sherbiny, Y., Rawstron, A.C., et al. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Ann Rheum Dis 73 (2014), 909–912.
111. Pascart, T., Philippe, P., Drumez, E., Deprez, X., Cortet, B., Duhamel, A., et al. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study. Int J Rheum Dis 19 (2016), 1093–1102.
112. Akiyama, M., Kaneko, Y., Kondo, H., Takeuchi, T., Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis. Clin Rheumatol 35 (2016), 2829–2834.
113. Aletaha, D., Smolen, J.S., Wong, J.B., Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 71 (2012), 1303–1308.
114. Finckh, A., Ciurea, A., Brulhart, L., Kyburz, D., Möller, B., Dehler, S., et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 56 (2007), 1417–1423.
115. Chatzidionysiou, K., van Vollenhoven, R.F., Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort. Scand J Rehabil Med 42 (2013), 190–195.
116. Soliman, M.M., Hyrich, K.L., Lunt, M., Watson, K.D., Symmons, D.P.M., Ashcroft, D.M., et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res 64 (2012), 1108–1115.
117. Harrold, L.R., Reed, G.W., Magner, R., Shewade, A., John, A., Greenberg, J.D., et al. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry. Arthritis Res Ther, 17, 2015, 256.
118. Gomez-Reino, J.J., Maneiro, J.R., Ruiz, J., Roselló, R., Sanmarti, R., Romero, A.B., et al. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR study. Ann Rheum Dis 71 (2012), 1861–1864.
119. Emery, P., Gottenberg, J.E., Rubbert-Roth, A., Sarzi-Puttini, P., Choquette, D., Taboada, V.M.M., et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis 74 (2015), 979–984.
120. Manders, S.H.M., Kievit, W., Adang, E., Brus, H.L., Moens, H.J.B., Hartkamp, A., et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Res Ther, 17, 2015, 134.
121. Backhaus, M., Kaufmann, J., Richter, C., Wassenberg, S., Roske, A.-E., Hellmann, P., et al. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice. Clin Rheumatol 34 (2015), 673–681.
122. Harrold, L.R., Reed, G.W., Kremer, J.M., Curtis, J.R., Solomon, D.H., Hochberg, M.C., et al. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis 74 (2015), 430–436.
123. Hirabara, S., Takahashi, N., Fukaya, N., Miyake, H., Yabe, Y., Kaneko, A., et al. Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies. Clin Rheumatol 33 (2014), 1247–1254.
124. Schwartz, D.M., Bonelli, M., Gadina, M., O'Shea, J.J., Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 12 (2016), 25–36.
125. Semerano, L., Decker, P., Clavel, G., Boissier, M.-C., Developments with investigational Janus kinase inhibitors for rheumatoid arthritis. Expert Opin Investig Drugs 25 (2016), 1355–1359.
126. Burmester, G.R., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381 (2013), 451–460.
127. Vieira, M.-C., Zwillich, S.H., Jansen, J.P., Smiechowski, B., Spurden, D., Wallenstein, G.V., Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysis. Clinical Therap 38 (2016), 2628–2641 e5.
128. Genovese, M.C., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374 (2016), 1243–1252.
129. Aletaha, D., Bingham, C.O., Tanaka, Y., Agarwal, P., Kurrasch, R., Tak, P.P., et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet 389 (2017), 1206–1217.
130. Crotti, C., Raimondo, M.G., Becciolini, A., Biggioggero, M., Favalli, E.G., Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. Drug Des Devel Ther 11 (2017), 211–223.
131. Weinblatt, M.E., Mcinnes, I.B., Kremer, J., Miranda, P., Vencovsky, J., Godwood, A., et al. Earth explorer 2, a phase IIb exploratory study evaluating efficacy and safety of mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor-alpha monoclonal antibody, and the tumor necrosis factor antagonist golimumab in rheumatoid arthritis. Ann Rheum Dis 75 (2016), S717–8.
132. Kremer, J.M., Emery, P., Camp, H.S., Friedman, A., Wang, L., Othman, A.A., et al. A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthritis Rheumatol 68 (2016), 2867–2877.